The purpose of this editorial is to consider some of the aspects of the diagnosis and treatment of adult gliomas. These are rare diseases with all their limitations. Innovations in diagnosis and therapy and their constraints are analyzed and compared with the current treatment reality. Aspects affecting these patients’ quality of life are highlighted.
OstromQTCioffiGWaiteK, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol2021; 23: iii1-iii105.
2.
LowJTOstromQTCioffiG, et al. Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. Neurooncol Pract2022; 9: 165-182.
3.
SinghGManjilaSSaklaN, et al. Radiomics and radiogenomics in gliomas: a contemporary update. Br J Cancer2021; 125: 641-657.
4.
LiaoXCaiBTianB, et al. Machine-learning based radiogenomics analysis of MRI features and metagenes in glioblastoma multiforme patients with different survival time. J Cell Mol Med2019; 23: 4375-4385.
5.
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomized controlled multicentre phase III trial. Lancet Oncol2006; 7: 392–401.
6.
De Witt HamerPCRoblesSGZwindermanAH, et al. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol2012; 30: 2559-2565.
7.
LouisDNPerryAReifenbergerG, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol2016; 131: 803–820.
8.
LouisDNPerryAWesselingP, et al. The 2021 WHO Classification of tumors of the central nervous system: a summary. Neuro Oncol2021; 23: 1231-1251.
9.
BarresiVGiannoFMarucciG. Newly recognised tumour types in glioneuronal tumours according to the 5th edition of the CNS WHO Classification. Pathologica2022; 114: 447-454.
BrownPDChungCLiuDD, et al. A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro Oncol2021; 23: 1337-1347.
12.
RudàR. Optimize treatment approaches in isocitrate dehydrogenase (IDH) mutant gliomas: open issues. Neuro Oncol2023; 25: 26-27.
13.
LaperriereNZurawLCairncrossG. Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol2002; 64: 259-273.
14.
FrosinaG. Improving control of high-grade glioma by ultra-hyper-fractionated radiotherapy. J Neurosci Res2022; 100: 933-946.
15.
StuppRMasonWPvan den Bent, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med2005; 352: 987-996.
16.
StuppRTaillibertSKannerAA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA2015; 314: 2535-2543.
17.
LassmanABHoang-XuanKPolleyMC, et al. Joint Final Report of EORTC 26951 and RTOG 9402: Phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors. J Clin Oncol2022; 40: 2539-2545.
18.
LassmanAB. Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?CNS Oncol2015; 4: 341-346.
19.
MellinghoffIKPenas-PradoMPetersKB, et al. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin Cancer Res2021; 27: 4491-4499.
20.
LimMWellerMIdbaihA, et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol2022; 24: 1935-1949.
21.
LiauLMAshkanKBremS, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol2023; 9: 112-121.
22.
BrownCEAlizadehDStarrR, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med2016; 375: 2561-2569.
23.
AnghileriEPatanèMDi IanniN, et al. Deciphering the labyrinthine system of the immune microenvironment in recurrent glioblastoma: recent original advances and lessons from clinical immunotherapeutic approaches. Cancers (Basel)2021; 13: 6156.
24.
RaviVMNeidertNWillP, et al. T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat Commun2022; 13: 925.
25.
MinLHodiFSKaiserUB. Corticosteroids and immune checkpoint blockade. Aging (Albany)2015; 7: 521-522.
26.
PlattenMBunseLWickA, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature2021; 592: 463-468.
27.
TralongoPMasoLDSurboneA, et al. Use of the word “cured” for cancer patients—implications for patients and physicians: the Siracusa charter. Curr Oncol2015; 22: e38–40.
28.
GiovagnoliARMenesesRFPaterliniC, et al. Cognitive awareness after treatment for high-grade glioma. Clin Neurol Neurosurg2021; 210: 106953.
SilvaggiFSilvaniALampertiEA, et al. Pathways of follow-up care in an Italian center: retrospective study on patients with gliomas II and III. Neurol Sci2022; 43: 1303-1310.
31.
RudàRAngileriFFIusT, et al. SINch Neuro-Oncology Section, AINO and SIN Neuro-Oncology Section. Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. J Neurosurg Sci2020; 64: 313-334.
32.
WellerMvan den BentMTonn, et al. European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol2017; 18: e315-e329.
33.
PascualJSGDuffauH. The need to consider return to work as a main outcome in patients undergoing surgery for diffuse low-grade glioma: a systematic review. Acta Neurochir (Wien)2022; 164: 2789-2809.
34.
De LucaCRConroyRMcCarthyMC, et al. Neuropsychological impact of treatment of brain tumors. Cancer Treat Res2009; 150: 277–296.
35.
MainDSNowelsCTCavenderTA, et al. A qualitative study of work and work return in cancer survivors. Psychooncology2005; 14: 992–1004.
36.
RasmussenDMElverdamB. The meaning of work and working life after cancer: an interview study. Psychooncology2008; 17: 1232–1238.
37.
Gonzalez CastroLNArrillaga-RomanyICBatchelorTT. Challenges and opportunities for clinical trials in patients with glioma. JAMA Neurol. Epub ahead of print 17January2023. DOI: 10.1001/jamaneurol.2022.4924.
38.
AielloKAAlterO. Platform-independent genome-wide pattern of DNA copy-number alterations predicting astrocytoma survival and response to treatment revealed by the GSVD formulated as a comparative spectral decomposition. PLoS One2016; 11: e0164546.
39.
LiHDuanYLiuN, et al. Value of DWI combined with magnetic resonance spectroscopy in the differential diagnosis between recurrent glioma and radiation injury: a meta-analysis. Int J Clin Pract2022Oct25; 2022: 1–9.
